ADVIA Centaur AFP and Atellica IM Alpha Fetoprotein (AFP)
Siemens Healthcare Diagnostics, Inc. · Decision date May 11, 2026
What did the FDA approve?
FDA records P930036/S026 as a supplement to PMA P930036, with the supplement type “Real-Time Process”. The recorded decision is approval, dated May 11, 2026.
FDA approval order statement
a change that will implement control system (medical decision pools and tiered standards) and a traceability (update to 22/216, 2nd WHO International Standard) change.
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Immunology
- Decision date
- May 11, 2026
- FDA change category
- Change Design/Components/Specifications/Material
Regulatory record facts
- Identifier
- P930036/S026
- Regulatory pathway
- PMA supplement
- Applicant
- Siemens Healthcare Diagnostics, Inc.
- Product code
- LOK
- Decision code
- APPR
- Decision date
- May 11, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: KIT, TEST, ALPHA-FETOPROTEIN FOR NEURAL TUBE DEFECTS.
- Applicant
- Siemens Healthcare Diagnostics, Inc.
- Product code
- LOK
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P930036/S026 received
Application receipt date recorded by FDA.
P930036/S026 · FDA decision
Real-Time Process
Timeline entries are records held by MedtechLedger for P930036. View FDA’s full supplement list.
Related devices and submissions
Explore the linked device profile
Other records with product code LOK
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
IMMULITE Systems AFPP010007/S028 | Siemens Healthcare Diagnostics, Inc. | PMA supplement | Sep 22, 2026 | FDA |
IMMULITE Systems AFPP010007/S027 | Siemens Healthcare Diagnostics, Inc. | PMA supplement | Aug 20, 2026 | FDA |
IMMULITE 2000 AFPP010007/S026 | Siemens Healthcare Diagnostics, Inc. | PMA supplement | Jul 27, 2026 | FDA |
ARCHITECT AFP; Alinity i AFP (LN 3P36/07P90)P120008/S032 | ABBOTT LABORATORIES | PMA supplement | May 11, 2026 | FDA |
IMMULITE 2000 AFPP010007/S025 | Siemens Healthcare Diagnostics, Inc. | PMA supplement | Apr 21, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Siemens Healthcare Diagnostics, Inc.
- Headquarters
- Not reported
- Brand website
- siemens-healthineers.com
- FDA applicant address
- 333 Coney St., East Walpole, MA, 02032
Sources and methodology
- Original FDA record: P930036/S026
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


